

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNITED GENE HIGH-TECH GROUP LIMITED

聯合基因科技集團有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

PROPOSED CHANGE OF COMPANY NAME

The Board proposes to change the English name of the Company from “United Gene High-Tech Group Limited” to “Innovative Pharmaceutical Biotech Limited” and to adopt the Chinese name of “領航醫藥及生物科技有限公司” as the Company’s new secondary name in place of “聯合基因科技集團有限公司”, subject to certain conditions as set out in the paragraph headed “Conditions of the Change of Company Name” below.

The Change of Company Name is subject to approval of the Shareholders by way of a special resolution at the AGM and approval of the Registrar of Companies in Bermuda. A circular containing, among others, details of the Change of Company Name, together with a notice to convene the AGM, will be despatched to the Shareholders.

PROPOSED CHANGE OF COMPANY NAME

Subject to certain conditions as set out in the paragraph headed “Conditions of the Change of Company Name” below, the board (the “**Board**”) of directors (the “**Directors**”) of United Gene High-Tech Group Limited (the “**Company**”) proposes to change the English name of the Company from “**United Gene High-Tech Group Limited**” to “**Innovative Pharmaceutical Biotech Limited**” and to adopt the Chinese name of “領航醫藥及生物科技有限公司” as the Company’s new secondary name in place of “聯合基因科技集團有限公司” (the “**Change of Company Name**”).

REASONS FOR THE CHANGE OF COMPANY NAME

The Company has recently expanded and diversified its business in pharmaceutical industry by acquisition of certain equity interest in Extrawell Pharmaceutical Holdings Limited (stock code: 858) and controlling interest in Smart Ascent Limited which engaged in the research and development of the oral insulin enteric-coated soft capsules. In order to highlight the new pharmaceutical business of the Company, the Board believes that the Change of Company Name would provide the Company with a fresh corporate identity and image which will benefit its future business development.

The Board is therefore of the opinion that the proposed Change of Company Name is in the interests of the Company and the shareholders of the Company (the “**Shareholders**”) as a whole.

CONDITIONS OF THE CHANGE OF COMPANY NAME

The proposed Change of Company Name is subject to the satisfaction of the following conditions:

1. the passing of a special resolution by the Shareholders approving the Change of Company Name at the forthcoming annual general meeting of the Company to be held on or around 25 August 2015 (the “**AGM**”); and
2. the Registrar of Companies in Bermuda approving the Change of Company Name.

Subject to the satisfaction of the conditions set out above, the Change of Company Name will take effect from the date of entry of the new English name and the new secondary name of the Company on the register of companies maintained by the Registrar of Companies in Bermuda. The Company will then carry out all necessary filing procedures with the Companies Registry in Hong Kong.

EFFECT OF CHANGE OF COMPANY NAME

The Change of Company Name will not affect any of the rights of the Shareholders. Once the Change of Company Name becomes effective, share certificates of the Company will be issued in the new name and the new secondary name of the Company. However, all existing share certificates in issue bearing the current name of the Company will, after the Change of Company Name has become effective, continue to be effective as documents of title to and be valid for trading, settlement, registration and delivery purposes. Accordingly, there will not be any arrangement for exchange of the existing share certificates of the Company for new share certificates bearing the new name and the new secondary name of the Company.

The Company expects to be traded in its new English name and the new secondary name as soon as the Change of Company Name becomes effective and the filing procedures in Hong Kong have been fulfilled. Further announcement(s) will be made by the Company to inform the Shareholders on the results of the AGM, the effective date of the Change of Company Name and the change of stock short names of the Company for trading of the shares on the Main Board of The Stock Exchange of Hong Kong Limited as and when appropriate.

GENERAL

A circular containing, among others, details of the Change of Company Name, together with a notice of the AGM, will be despatched to the Shareholders in due course.

By Order of the Board
United Gene High-Tech Group Limited
Lee Nga Yan
Executive Director

Hong Kong, 20 July 2015

As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Ms. Lee Nga Yan (executive Director), Dr. Guo Yi (executive Director), Mr. Tang Rong (executive Director), Ms. Xiao Yan (non-executive Director), Ms. Wu Yanmin (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Dr. Zhang Zhihong (independent non-executive Director) and Mr. Wang Rongliang (independent non-executive Director).